Taking it Personally; Biotech Patents  

Oleh:

[s.n]

Jenis: Article from Bulletin/Magazine
Dalam koleksi: The Economist (http://search.proquest.com/) vol. 401 no. 8763 (Dec. 2011), page 64-65.
Topik: Research & Development--R&D; Pharmaceutical Industry; Health Care; Litigation; Biotechnology; Patents
Fulltext: Biotech Patents.pdf (36.37KB)

Ketersediaan

Perpustakaan Pusat (Semanggi) Nomor Panggil: EE29.69 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Drug research is in dark times, as pipelines dry up and development budgets are cut. But one shaft of light pierces the gloom. "Personalised medicine" promises to craft drugs for individuals. Genetic tests will identify those who will benefit from specific medicines. Treatment will be more effective; waste will drop. Personalised medicine has sparked excitement among drugmakers, doctors, hospitals and patients. It has also sparked a legal brawl. On December 7th America's Supreme Court heard arguments in Mayo v Prometheus. The suit, despite a name that suggests an ancient liver sandwich, may be crucial for biotechnology firms. America is the world's hub for drug research. By definition, personalised medicine includes the study of genetic mutations and other personal characteristics. However, American law bars patents of nature and abstract ideas. The question is which discoveries in personalised medicine may be patented. Prometheus is part of a series of suits over biotech patents.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali